Delving into the Latest Updates on SHR-2002 with Synapse

Overview

Basic Info

Drug Type

Bispecific antibody

Synonyms

SHR 2002, SHR-2002, SHR2002

Target

CD112R x TIGIT

Mechanism

CD112R antagonists(Transmembrane protein PVRIG antagonists), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors)

Therapeutic Areas

Neoplasms

Active Indication

Advanced cancerSolid tumor

Inactive Indication-

Originator Organization

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Active Organization

Shanghai Hengrui Pharmaceutical Co., Ltd.Atridia Pty Ltd.

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

To evaluate the safety and tolerability of SHR-2002 alone or in combination with SHR-1316 in patients with advanced malignant tumors, and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and the recommended dose (RP2D) for Phase II clinical studies of SHR-2002 combined with SHR-1316.

Start Date22 Feb 2022

Sponsor / Collaborator

Shanghai Hengrui Pharmaceutical Co., Ltd.

[+1]

NCT05082545 / CompletedPhase 1

A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SHR-2002 Injection in Combination With SHR-1316 in Patients With Advanced Malignant Tumors

This is Phase 1 study FIH to check "Dose Escalation, Dose expansion and Indication expansion". This study is AUSTRALIA only study.

Start Date23 Nov 2021

Sponsor / Collaborator

Atridia Pty Ltd.

100 Clinical Results associated with SHR-2002

Login to view more data

100 Translational Medicine associated with SHR-2002

Login to view more data

100 Patents (Medical) associated with SHR-2002

Login to view more data

100 Deals associated with SHR-2002

Login to view more data